PharmaMar announced the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis, throughout the Nordic countries and Eastern Europe. This agreement will come into effect in six months.
According to the terms of the agreement, PharmaMar will receive an up-front payment of 2 million euros. Impilo Pharma will be responsible for the promotion and the distribution of Yondelis throughout the above mentioned territories, and PharmaMar will be the manufacturer of the product.
This agreement will replace the current contract between PharmaMar and Swedish Orphan Biovitrum International for the promotion and distribution of Yondelis in the Nordic countries and Eastern Europe.
"This agreement will help us to strengthen the sales of Yondelis even more throughout various European Countries, also maintaining our compromise with the patients, facilitating their access to novel therapies," said Luis Mora, Managing Director of the Oncology Business Unit at PharmaMar.